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Chapter 4 Diagnosis
At the turn of the century, it was widely recognized that an accurate point-of care test for TB was required to make
significant reductions in the pandemic. At this time, many novel tests had been developed by research groups or small
biotech companies, but had never been standardized or evaluated for scale-up and application in low-resource, high-
burden settings where the need is greatest. This motivated a major drive to systematically evaluate existing tests such
as commercial liquid culture and nucleic acid amplification tests (NAAT), and to develop new approaches, principally
led by the Foundation for Innovative New Diagnostics (FIND www.finddiagnostics.org) in collaboration with
industry, government and clinical partners. The evidence generated by this renewed focus on novel TB diagnostic
tests, processes and algorithms has led to a substantial number of policy revisions and new WHO recommendations
(Table 4.1, see also www.tbevidence.org).
4.1. Smear Microscopy
The confirmation of TB disease still rests upon identification or isolation of M. tuberculosis bacilli from a clinical
sample. This can be achieved by smear microscopy for acid-fast bacilli (AFB), mycobacterial culture or nucleic acid
amplification (NAAT) tests. The appropriate sample will depend upon the suspected site of disease. The quality of the
sample may greatly affect the chances of a positive result therefore care should be taken to instruct the patient in
producing a sputum sample. Children are often unable to produce sputum and in young children gastric aspirate is
usually necessary.
Diagnosis for the majority of patients worldwide suspected of TB is still made by sputum smear microscopy for acid-
fast bacilli. The test, which was developed 100 years ago by Franz Ziehl and Frederick Neelsen, is inexpensive,
simple, rapid and specific but is only positive in around half of patients with active TB. The Ziehl-Neelsen smear
exploits the acid-fast property of mycobacteria by staining bacilli with carbol-fuschin, using gentle heat to facilitate
penetration of the dye, and then using a decolorising acid solution, which fails to penetrate the mycobacteria, leaving
them stained red while other bacilli are decolorised. The slide is usually then counterstained with methylene blue to
improve visualization of the mycobacteria (World Health Organisation 1998). The Kinyoun stain is an alternative
cold-stain method. The sensitivity of the test is substantially lower in children and patients with HIV. In addition the
test is not specific for M. tuberculosis, but detects all acid-fast bacilli including NTMs. Sensitivity may be increased
by concentration of samples prior to microscopy, usually by centrifugation or filtration (Van Deun et al. 2000) but
direct (unconcentrated) ZN stain is the most widely applied methodology due to resource limitations.
Traditional TB control focused on the identification and treatment of sputum smear-positive TB patients, considered
to be most infectious cases, in the mistaken belief that systematic identification and treatment of smear-positive cases
would be sufficient to reach eventual TB elimination. Recent efforts to improve the sensitivity of basic smear
microscopy have developed improved fluorescent microscopes to decrease the reading time and increase the
sensitivity of smear microscopy without significantly affecting specificity if training and quality control are
maintained. WHO now recommends the replacement of conventional microscopy with fluorescent microscopy
wherever possible, using rugged and energy efficient LED fluorescent microscopes that can be battery operated. In a
further policy change, WHO recommended in 2010 that two sputum samples are sufficient, rather than the standard
three samples (spot-morning-spot) which had been recommended for several decades (World Health Organisation
2010). This is due to the low diagnostic yield of a third sputum sample and the resource limitations of TB
programmes. If clinical suspicion is high repeated testing may still be warranted. A single positive smear is now also
considered sufficient for a TB diagnosis (Bonnet et al. 2007; Mase et al. 2007).
4.2. Mycobacterial Culture
Culture of M. tuberculosis is a more sensitive technique for diagnosis but due to the slow growth of the organism
(replication time of 24–30 h) sputum cultures take 4–6 weeks to become positive on solid media and 10–21 days in
liquid media. Solid culture is usually performed on Lowenstein Jensen (LJ), Ogawa or Middlebrook 7H10/11 agar
media. Liquid culture of M. tuberculosis is more sensitive and rapid than solid culture but can be prone to
contamination in some laboratories. Early commercial automated liquid culture systems for mycobacteria used
radiometric assay but have now been replaced with fluorescence based quenching systems which has improved safety.
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The most widely used system is the Bactec Mycobacterial Growth Indicator Tube (MGIT) (Becton Dickinson, Sparks,
Massachusetts) system which can also be used for susceptibility testing to first line drugs using a commercially
available kit. A culture is necessary to confirm drug susceptibility, particularly for second-line drugs in cases of multi-
drug resistance (MDR TB). M. tuberculosis culture and phenotypic DST requires significant training, infrastructure,
strict infection control and on-going quality assurance, which is only available in regional reference laboratories in
most countries
4.3. Nucleic Acid Amplification Tests
Various commercial and in-house nucleic acid amplification tests (NAAT) have been available since the 1990s.
Detection of M. tuberculosis in clinical samples is generally less sensitive than NAAT for other pathogens due to the
relatively low numbers of bacilli present and the difficulty of efficiently extracting DNA from the tough
mycobacteria. The development of Line Probe assays (LPA) allowed the simultaneous detection of M. tuberculosis
and determination of resistance to rifampicin and later isoniazid. However these tests are only endorsed for use on
smear positive sputum and therefore do not aid greatly in the diagnosis of TB itself. The MTBDR-Plus assay
(HainLifesciences, Nehren, Germany) has recently been adapted to enhance detection for use on smear negative
sputum samples but large-scale evaluation data is not yet available. The use of LPA for detection of drug resistance is
discussed in more detail in the section on diagnosis of drug resistance below.
The most significant advance in the diagnosis of TB in the last decade has been the advent of the GeneXpert
MTB/RIF test (Cepheid, California, USA). This test system was originally developed for testing for the presence of
anthrax spores in the United States bioterrorism-scares. A specific cartridge was later developed to detect M.
tuberculosis and simultaneously determine resistance to rifampicin. In 2010 results of a multi-country demonstration
study sponsored by FIND demonstrated that the Xpert MTB/RIF test detected TB and rifampicin resistance with high
sensitivity and specificity compared to liquid culture; confirmed by a Cochrane review in 2013. The test was officially
endorsed by WHO, followed by an unprecedented rapid scale up of the new technology
[http://who.int/tb/laboratory/mtbrifrollout/en/]. A key factor in wide-scale implementation was a negotiated price
reduction facilitated by a large guaranteed buy-down from UNITAID, USAID, PEPFAR and the Bill and Melinda
Gates Foundation which reduced the price per cartridge from more than 40 USD to less than 10 USD for public health
facilities in 141 low and middle income countries. A major advantage of the Xpert MTB/RIF test is the ability to
detect smear negative TB in HIV-infected individuals (World Health Organization 2013).
In 2013 WHO issued updated policy guidance on the use of Xpert MTB/RIF additionally endorsing its application for
extrapulmonary and pediatric samples. This policy update expanded the recommended application of Xpert MTB/RIF
to include pediatric and extrapulmonary samples, including gastric aspirate, lymph aspirate, pleural fluid and
cerebrospinal fluid. There was insufficient evidence to estimate sensitivity with urine, pericardial fluid and ascitic
fluid, although specificity is generally high with these sample types. Optimal sample processing for blood and stool
samples has not been determined and therefore the Xpert MTB/RIF test is not recommended pending further research.
Full recommendations can be found at http://tbevidence.org/wp-content/uploads/2013/11/WHOstat.pdf.
By facilitating early detection of TB, prior to smear positivity, the application of Xpert MTB/RIF should have a
significant impact on transmission chains and push back the epidemic. However, many of the patients diagnosed by
Xpert MTB/RIF would have been initiated on treatment due to chest X-ray findings or clinical findings consistent
with TB and the extent to which the use of Xpert MTB/RIF will increase case finding is not yet clear. Theoretical
modelling studies suggest that the application of the test will improve targeting of treatment, with less patients who do
not have TB incorrectly started on treatment and a greater number of smear negative ‘true TB’ cases detected. South
Africa has implemented the Xpert MTB/RIF test nationwide and data on the cost-effectiveness and impact on the
epidemic are eagerly awaited. Although relatively simple to perform and rapid, the Xpert MTB/RIF is not a true
point-of-care test and many challenges have been encountered during scale-up. The need for a reliable electricity
supply is a major barrier in some settings, problems with module calibration and maintenance, the need for the bulky
cartridges to be stored below 30 °C, determining optimal testing algorithms and logistics of kit supply have been some
of the challenges encountered (Abdurrahman et al. 2014) (Fig. 4.1).
4.4. Diagnosing Drug-Resistant Tuberculosis
A major impact of the scale-up of Xpert MTB/RIF is increased detection of RIF resistance, which is a surrogate
marker for MDR TB. Classical diagnosis of drug resistance in M. tuberculosis involves culture of the bacilli on solid
or liquid media and comparison of growth between drug-free and drug containing media. Even with the advent of
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direct liquid culture methodology, detection of drug resistance takes over two weeks, and with indirect methods, two
months or more. Standardisation of drug susceptibility testing for the antituberculous drugs is difficult and should be
performed in a biosafety level 3 laboratory by trained personnel participating in an external quality assurance scheme.
Isoniazid, rifampicin and streptomycin are the most reliable drug susceptibility tests.
Molecular detection of drug resistance mutations provides a rapid alternative, but the accuracy of these tests varies
according to the drug. Rifampicin resistance detection is the most accurate, as 95 % of phenotypically rifampicin
resistant strains carry a mutation in the 81 base pair rifampicin—resistance-determining-region (RRDR) of the rpoB
gene. For isoniazid, molecular methods can detect approximately 75 % of phenotypically resistant strains by detecting
mutations in the katG gene or InhA promoter region. Development of commercial NAAT for the other antituberculous
drugs has been hampered by incomplete understanding of the molecular mechanisms of resistance. The principal
commercial NAAT for drug resistance are the Xpert MTB/RIF test and the line probe assays. The most recent pooled
estimates for M. tuberculosis detection by Xpert MTB/RIF were sensitivity of 88 % (95 %CI; 83–92%) and
specificity of 98 % (95 %CI; 97–99 %); for rifampicin resistance sensitivity 94 % (95 %CI; 87–97 %) and specificity
98 % (95 %CI; 97–99 %) (Steingart et al. 2014). Line Probe assays detect both rifampicin and isoniazid resistance
simultaneously and the MTBDR-sl assay detects resistance to fluoroquinolones, ethambutol and aminoglycosides.
The MTBDR-sl test has high sensitivity for fluoroquinolones, but low sensitivity for aminoglycoside and ethambutol
resistance (Feng et al. 2013). However, specificity is high for all drugs and therefore the test can be used to detect
resistance but should not be used to rule-out resistance. Unfortunately, the need remains to confirm susceptibility by
laborious phenotypic DST. Rapid sequencing techniques provide more comprehensive drug susceptibility data but are
not yet widely available beyond research settings.
Several non-commercial phenotypic DST approaches have been developed including microscopic observation drug
susceptibility testing (MODS), nitrate reductase assay (NRA) and colorimetric redox indicator (CRI) tests. A MODS
test kit is now available to improve standardization (Hardy diagnostics). In 2010 WHO issued a recommendation that
MODS could be used as an ‘interim’ approach for increased DST in high-burden countries but concluded that there
was insufficient data to recommend NRA or CRI. Reservations particularly around biosafety and quality control have
limited scale-up of the techniques (Image 4.1).
4.5. Other Diagnostic Methods
In 2011 WHO issued an unprecedented negative advisory on the use of serodiagnostic tests for TB (Steingart et al.
2011). These tests are appealing because of they are simple, rapid, inexpensive and non-invasive and are marketed
with claims of high sensitivity and specificity. However, systematic evaluation of 19 commercially available tests
using a well-characterised serum bank, and systematic review of all published studies concluded that none was
accurate for use in clinical practice (Steingart et al. 2011). The search for accurate biomarkers for use in
serodiagnostic tests continue, but has so far yielded little promise. Tests under evaluation by the Foundation for
Innovative New Diagnostics (FIND; www.finddiagnostics.org) include the loop-mediated isothermal amplification
test (LAMP) assay, mobile NAAT devices, volatile organic compound (VOC) or ‘electronic nose’ tests, an adapted
interferon-gamma release assay, and enzymatic detection systems. It is unlikely that a true point-of-care test for TB
will be available in the next 2–3 years given the current pipeline of diagnostic tests under evaluation (Thwaites et al.
2003; UNITAID 2014) (Fig. 4.2).
4.6. Diagnosing Latent Tuberculosis Infection
The interferon gamma release assays (IGRA) were developed as an alternative to the tuberculin skin test which is
confounded by BCG vaccination. Two commercial IGRAs are currently FDA approved for the diagnosis of M.
tuberculosis infection: The QuantiFERON-TB Gold In-Tube test (QFT-GIT) (Cellestis Limited, Carnegie, Victoria,
Australia, approved 2007); T-Spot test (Oxford Immunotec Limited, Abingdon, United Kingdom, approved 2008).
Whole blood or Peripheral blood mononuclear cells (PBMC) are stimulated with antigens from M. tuberculosis and
the interferon gamma release stimulated is measured. IGRA which use ESAT-6 and CFP-10 antigens for stimulation
are not confounded by prior BCG vaccination because these antigens are found in a region (RD1) of the M.
tuberculosis genome which is deleted from BCG and thought to be partially responsible for the loss of virulence.
In the United States, IGRA are widely used for the diagnosis of latent TB infection and are recommended by CDC
guidelines (available at: http://www.cdc.gov/mmwr/pdf/rr/rr5905.pdf). WHO do not recommend the use of IGRA in
endemic settings or for the diagnosis of active TB. It should be noted that 95 % of IGRA positive individuals do not
go on to develop active TB and therefore the predictive value of a positive IGRA is extremely low; no statistically
23-4-2020 Diagnosis - Tuberculosis in Adults and Children - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK344401/?report=printable 4/10
significant difference in the incidence of active TB between IGRA positive and IGRA negative individuals has been
demonstrated in the small number of studies which have addressed this question.
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Figures
Fig. 4.1 Current development in TB diagnostics. Only the Xpert® MTB/RIF has received WHO
endorsement. From UNITAID, Diagnostic technology and market landscape, 3rd edition, 2014.
Reprinted with permission
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Image 4.1 Mycobacterial cording in MODS. Image courtesy of Dr. Dang Thi Minh Ha
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Fig. 4.2 Current FIND TB diagnostics pipeline listing the development phases and the types of
technologies in development or evaluation, from UNITAID diagnostic technology and market
landscape, 2014, reprinted with permission
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Tables
Table 4.1 Laboratory tests for diagnosis of active tuberculosis and drug resistance











Recommended Inexpensive, simple, rapid, specific Cannot differentiate
NTM  and M.
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LED microscopy Recommended Inexpensive, simple, rapid Cannot differentiate
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Details of policy guidance at: http://www .who.int/tb/laboratory/en/
NTM: non-tuberculous mycobacteria
Reliable for first-line drugs (except pyrazinamide), fluoroquinoloes and aminoglycosides. Second-line DST should be interpreted in
context of treatment history and local prevalence of resistance (if known)
Indicator well must be incorporated to differentiate NTM from M. tuberculosis
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